Brevan Howard Capital Management LP Arcus Biosciences, Inc. Transaction History
Brevan Howard Capital Management LP
- $14.2 Billion
- Q3 2024
A detailed history of Brevan Howard Capital Management LP transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 10,322 shares of RCUS stock, worth $159,991. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,322
Previous 30,963
66.66%
Holding current value
$159,991
Previous $471,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RCUS
# of Institutions
200Shares Held
51.5MCall Options Held
236KPut Options Held
141K-
Black Rock Inc. New York, NY9.76MShares$151 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.47MShares$84.8 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.48MShares$53.9 Million0.48% of portfolio
-
State Street Corp Boston, MA3.01MShares$46.7 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.44MShares$37.8 Million0.1% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.12B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...